#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

Drug development transforms scientific discovery into clinical reality through a rigorous, multi-year process of identifying unmet medical needs, selecting therapeutic targets, and navigating complex regulatory hurdles. Physician-scientist Dr. Lloyd Klickstein illustrates this journey using bimagrumab, a monoclonal antibody initially developed for sarcopenia. The conversation details the technical distinctions between small molecules and biologics, the critical role of intellectual property in funding high-cost innovation, and the challenges of establishing clinical endpoints that accurately reflect patient outcomes. Key insights include the necessity of failing fast during preclinical phases, the impact of patient nutrition on drug efficacy, and the evolution of obesity treatments from standalone therapies to combination regimens. This exploration highlights the immense complexity of bringing a drug from a laboratory concept to a viable treatment for metabolic disease, emphasizing the balance between rigorous safety standards and the pursuit of meaningful therapeutic innovation.